

1 **Title:** Distinct respiratory tract biological pathways characterizing ARDS molecular
2 phenotypes

3 **Authors:** Aartik Sarma¹, Stephanie A. Christenson¹, Beth Shoshana Zha¹, Angela Oliveira
4 Pisco², Lucile P.A. Neyton¹, Eran Mick^{2,3}, Pratik Sinha⁴, Jennifer G. Wilson⁵, Farzad Moazed¹,
5 Aleksandra Leligdowicz^{6,7}, Manoj V. Maddali⁸, Emily R. Siegel⁹, Zoe M. Lyon⁹, Hanjing Zhou¹,
6 Alejandra Jauregui¹, Rajani Ghale¹, Saharai Caldera², Paula Hayakawa Serpa^{2,3}, Thomas
7 Deiss¹, Christina Love², Ashley Byrne², Katrina L. Kalantar², Joseph L. DeRisi², David J.
8 Erle^{6,10,11,12}, Matthew F. Krummel^{11,13}, Kirsten N. Kangelaris¹⁴, Carolyn M. Hendrickson¹⁵,
9 Prescott G. Woodruff^{1,6}, COMET Consortium, Michael A. Matthay^{1,6,16}, Charles R. Langelier^{2,3},
10 Carolyn S. Calfee^{1,6,16}

11 **Affiliations:**

- 12 1. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of
13 Medicine, University of California San Francisco, CA
- 14 2. Chan Zuckerberg Biohub, San Francisco, CA
- 15 3. Division of Infectious Diseases, Department of Medicine, University of California San
16 Francisco, CA
- 17 4. Department of Anesthesia, Washington University in St Louis
- 18 5. Department of Emergency Medicine, Stanford University School of Medicine, Stanford
19 University, Stanford, CA
- 20 6. Cardiovascular Research Institute, University of California San Francisco, CA
- 21 7. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto,
22 Ontario, Canada
- 23 8. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine,
24 Stanford University, Stanford, CA
- 25 9. School of Medicine, University of California San Francisco, CA
- 26 10. Lung Biology Center, University of California San Francisco, CA
- 27 11. Bakar ImmunoX Initiative, University of California San Francisco, CA
- 28 12. UCSF CoLabs, University of California San Francisco, CA
- 29 13. Department of Pathology, University of California San Francisco, CA
- 30 14. Division of Hospital Medicine, University of California San Francisco, CA
- 31 15. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Zuckerberg
32 San Francisco General Hospital and Trauma Center, University of California San
33 Francisco
- 34 16. Department of Anesthesia, University of California San Francisco, CA

35
36 Word count: 3,493

37 **Abstract:**

38 **Background:** Two molecular phenotypes of the acute respiratory distress syndrome (ARDS)
39 with divergent clinical trajectories and responses to therapy have been identified. Classification
40 as “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling.

41 Differences in pulmonary biology underlying these phenotypes are unknown.

42 **Methods:** We analyzed tracheal aspirate (TA) RNA sequencing (RNASeq) data from 41 ARDS
43 patients and 5 mechanically ventilated controls to assess differences in lung inflammation and
44 repair between ARDS phenotypes. In a subset of subjects, we also analyzed plasma proteomic
45 data. We performed single-cell RNA sequencing (scRNASeq) on TA samples from 9 ARDS
46 patients. We conducted differential gene expression and gene set enrichment analyses, *in silico*
47 prediction of pharmacologic treatments, and compared results to experimental models of acute
48 lung injury.

49 **Findings:** In bulk RNASeq data, 1334 genes were differentially expressed between ARDS
50 phenotypes (false detection rate < 0.1). Hyperinflammatory ARDS was characterized by an
51 exaggerated innate immune response, increased activation of the integrated stress response,
52 interferon signaling, apoptosis, and T-cell activation. Gene sets from experimental models of
53 lipopolysaccharide lung injury overlapped more strongly with hyperinflammatory than
54 hypoinflammatory ARDS, though overlap in gene expression between experimental and clinical
55 samples was variable. ScRNASeq demonstrated a central role for T-cells in the
56 hyperinflammatory phenotype. Plasma proteomics confirmed a role for innate immune
57 activation, interferon signaling, and T-cell activation in the hyperinflammatory phenotype.
58 Predicted candidate therapeutics for the hyperinflammatory phenotype included imatinib and
59 dexamethasone.

60 **Interpretation:** Hyperinflammatory and hypoinflammatory ARDS phenotypes have distinct
61 respiratory tract biology, which could inform targeted therapeutic development.

- 62 **Funding:** National Institutes of Health; University of California San Francisco ImmunoX
- 63 CoLabs; Chan Zuckerberg Foundation; Genentech
- 64
- 65 Abstract word count: 246 without funding

66 **Introduction**

67 The acute respiratory distress syndrome (ARDS) is characterized by noncardiogenic
68 pulmonary edema and hypoxemia within one week of a physiologic insult¹. The global incidence
69 of ARDS has surged during the COVID-19 pandemic, increasing the importance of finding
70 effective treatments. While some pharmacologic interventions have decreased mortality in
71 patients with severe COVID-19^{2,3}, no drug has consistently reduced mortality in more typical
72 heterogeneous cohorts of patients with ARDS. There is a growing recognition that biological
73 heterogeneity within the syndrome is a significant barrier to identifying effective treatments⁴.

74 Two clinically distinct molecular phenotypes of ARDS (termed “hyperinflammatory” and
75 “hypoinflammatory”) have been identified using latent class analysis of clinical and plasma
76 biomarker data in eight cohorts^{1,5-11}. The hyperinflammatory phenotype is characterized by
77 elevated plasma inflammatory cytokines (IL-8, IL-6, TNFr-1), lower plasma Protein C and
78 bicarbonate, and higher mortality compared to the hypoinflammatory phenotype. Importantly,
79 significant differences in treatment response to simvastatin, ventilator settings, and fluid
80 management have been observed across molecular phenotypes in retrospective analyses of
81 three ARDS clinical trials^{5,6,11}; further, in patients with COVID-19-related ARDS,
82 hyperinflammatory patients may preferentially respond to corticosteroid treatment^{12,13}. These
83 results suggest that understanding and targeting the heterogeneous biology underlying ARDS
84 molecular phenotypes is essential to identifying effective new treatments for ARDS. Prospective
85 studies designed to identify these phenotypes using parsimonious models are laying the
86 groundwork for precision clinical trials^{4,14}.

87 Despite this exciting progress, a critical barrier to developing new therapies for ARDS is
88 the limited understanding of the biological pathways characterizing each phenotype. This
89 knowledge gap was recently cited by NHLBI and European Respiratory Society workshops on
90 precision medicine in ARDS as a top research priority for the field^{4,15}. To date, analyses of the
91 biological differences between these phenotypes have been largely limited to circulating

92 biomarkers, due to the relative ease of sampling. Understanding the biological differences
93 between ARDS molecular phenotypes in the lung, the active site of injury, will be critical to
94 development of informative pre-clinical models of disease and targeted treatments for ARDS.
95 Here, we employ a systems biology approach incorporating bulk and single-cell RNA-
96 sequencing, *in silico* analyses, and proteomics to understand differences in lung immunology
97 and inflammatory responses between ARDS phenotypes.

98

99 **Methods:**

100 **Study subjects**

101 Subjects were enrolled in two prospective observational cohorts of critically ill patients.
102 We used bulk RNASeq data and plasma proteomic data from the Acute Lung Injury in Critical
103 Illness (ALI) study, a cohort of mechanically ventilated adults admitted to the intensive care unit
104 at the University of California, San Francisco Medical Center (UCSFMC) between July 2013 and
105 March 2020. We used single-cell RNA-Sequencing (scRNASeq) data from the COVID-19
106 Multiphenotyping for Effective Therapies (COMET) study, a study of hospitalized patients with
107 COVID-19 or other acute respiratory illnesses admitted to UCSFMC or Zuckerberg San
108 Francisco General Hospital (ZSFGH). COVID-19 status was confirmed by clinical PCR testing
109 and metagenomic sequencing. These studies were approved by the UCSF Institutional Review
110 Board (17-24056, 20-30497), which granted an initial waiver of informed consent to collect TA
111 and blood samples. Informed consent was then obtained from patients or surrogates, as
112 previously described¹⁶.

113 In this analysis, we included all available subjects in each cohort who were admitted to
114 the intensive care unit for mechanical ventilation for ARDS or for airway protection without
115 radiographic evidence of underlying pulmonary disease. For non-ARDS control patients in the
116 ALI study, we excluded subjects on immunosuppression, including corticosteroids, and those
117 with immunocompromising conditions (e.g., bone marrow transplant recipients).

118

119 **ARDS adjudication and phenotype assignment**

120 Electronic health records were adjudicated for ARDS (Berlin Definition¹⁷) by at least two
121 clinicians blinded to all biological data. Lower respiratory tract infections were diagnosed using
122 the CDC surveillance definition¹⁸. ARDS phenotype was determined using a validated three-
123 variable classifier model (IL-8, protein C, and bicarbonate)¹⁴. Subjects with a probability of class
124 assignment greater than 0.5 were assigned to the hyperinflammatory phenotype. Plasma
125 biomarkers were not available for five subjects with TA bulk RNA sequencing. For these
126 subjects, we used a validated clinical classifier model to assign phenotype^{10,19}.

127

128 **Tracheal aspirate sampling and RNA sequencing**

129 Following enrollment in the ALI cohort, TA was collected within three days of intubation.
130 In the COMET cohort, TA samples were collected daily, and the first available sample collected
131 within three days of enrollment was used for this analysis. For bulk RNA sequencing, TA was
132 collected and stored in DNA/RNA Shield (Zymo, Inc.) at -80C¹⁶. Samples underwent library
133 preparation and Illumina paired-end sequencing using established methods described in detail
134 in the online supplement. For scRNASeq, TA was collected and processed within 3 hours as
135 previously described²⁰.

136

137 **Cell annotation, differential expression, pathway, and network analysis**

138 We performed pairwise comparisons of gene expression in each ARDS phenotype and
139 controls using *DESeq2*. Single cell transcriptomes were annotated using *SingleR*. We compared
140 gene expression between phenotypes for each cell type using *MAST*, using a mixed effects
141 model with fixed effects for phenotype and cellular detection rate and a random effect for
142 subject. Differentially expressed genes were then analyzed using Ingenuity Pathway Analysis
143 (IPA, Qiagen). Full details of cell annotation, differential gene expression, and IPA analyses are

144 provided in the online supplement. To study how cell-cell signaling contributed to observed
145 differential expression, we used *CellChat*²¹ to infer intercellular communication networks by
146 comparing scRNASeq data to a curated database of ligands, receptors, and their cofactors.

147

148 **Plasma proteomic analysis**

149 Plasma samples from the Acute Lung Injury in Critical Illness cohort and 14 healthy
150 controls from a previously published dataset²² were analyzed using the O-link Proteomics
151 Assay, which generates a semi-quantitative measurement of 96 plasma proteins. We excluded
152 all samples that were flagged with a QC warning from the O-link platform and excluded any
153 biomarker for which protein concentrations could not be measured for at least 90% of samples.
154 Measurements for 73 proteins passed the manufacturer's quality control filter and were included
155 for analysis. Normalized protein expression measurements were compared using a Wilcoxon
156 rank-sum test and p-values were adjusted using the Benajmini-Hochberg method (FDR < 0.1).

157

158 **Comparison of differentially expressed genes to experimental models of acute lung 159 injury**

160 We identified experimental models of acute lung injury in the Gene Expression Omnibus.
161 Lists of all genes differentially expressed at a Benjamini-Hochberg adjusted p-value less than
162 0.05 were downloaded using GEO2Enrichr²³. We then used the genes that were upregulated in
163 the experimental lung injury model as gene signatures in GSVA²⁴ (Supplemental Data 3A). If
164 more than 200 genes were differentially expressed in the experimental model, we used the top
165 200 genes (by p-value) for the experimental gene signature. We used *limma*²⁵ to compare
166 GSVA scores in samples from each phenotype to GSVA scores in controls.

167

168 **Results**

169 **Patient Characteristics: Acute Lung Injury in Critical Illness Cohort**

170 In the Acute Lung Injury in Critical Illness cohort, TA sequencing data was available for
171 41 ARDS participants and five controls (Figure S1). Ten of 41 ARDS subjects (24%) were
172 classified as the hyperinflammatory phenotype, consistent with the proportion observed in
173 previous studies^{5-8,11}. There were no significant differences in age, sex, BMI,
174 immunosuppression, respiratory viral or bacterial infections, or ARDS risk factors between
175 hyperinflammatory and hypoinflammatory patients (Table 1).

176

177 **Bulk RNA-Sequencing**

178 1,334 genes were differentially expressed between ARDS phenotypes with an absolute
179 empirical Bayesian posterior log₂-fold change >0.5 (Figure S2A, Supplementary Data S1A). IPA
180 predicted increased activation of several cytokines and other upstream regulators of
181 differentially expressed genes in hyperinflammatory ARDS, compared with hypoinflammatory
182 ARDS (Figure 1A, Supplementary Data S2A). These included several cytokines classically
183 associated with an innate response previously found to be elevated in plasma of patients with
184 hyperinflammatory ARDS, including IL1B, IL6, and TNF. In addition, IPA identified activation of
185 cytokine responses not previously studied in hyperinflammatory ARDS, including numerous
186 interferon-stimulated genes; IL2 and IL15, which stimulate cytotoxic T cell and NK cell
187 responses²⁶; and the chemokine ligand CCL2/MCP-1. Upstream regulator analysis predicted
188 increased activation of transcriptional regulators critical to the integrated stress response
189 (XBP1, NFE2L2) and increased cellular differentiation (MYC, NONO), as well as stimulation of
190 Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) and receptors integral to T cell activation
191 (CD3, CD28) in hyperinflammatory ARDS.

192 To further understand how pathways in each phenotype were dysregulated, we
193 compared each phenotype to mechanically ventilated control patients with neurologic injury.
194 2,989 genes were differentially expressed between hyperinflammatory ARDS and controls
195 (Figure S2B, Supplementary Data 1C), while 2,132 genes were differentially expressed between

196 hypoinflammatory ARDS and controls (Figure S2C, Supplementary Data 1D). Notably,
197 upstream regulator analysis identified several cytokines that were activated in both
198 hyperinflammatory and hypoinflammatory ARDS compared to controls (Figure 1C,
199 Supplementary Data 2C and 2D), including IL1B, TNF, and IFNG. While this analysis identified
200 some similarities between phenotypes, it also confirmed that several upstream regulators that
201 were activated in pairwise comparisons of hyperinflammatory ARDS to hypoinflammatory ARDS
202 and hyperinflammatory ARDS to controls, suggesting these upstream regulators play an
203 important role in the distinct features of hyperinflammatory ARDS. These included IL6, which
204 was one of plasma cytokines used to define the hyperinflammatory phenotype⁵; IL18, which was
205 not measured in the original LCA studies, but, like the hyperinflammatory phenotype, was
206 associated with higher mortality and a response to simvastatin in the HARP-2 trial²⁷; the T cell
207 receptor; Type I/III interferons (IFNA, IFNL, IFNB), indicative of an enhanced mucosal interferon
208 response²⁸; several Toll-like receptors (TLR2/3/9); and FAS, which stimulates apoptosis²⁹. In
209 addition, several upstream regulators associated with specific immune cells were predicted to
210 be activated in hyperinflammatory ARDS but not in hypoinflammatory ARDS, including markers
211 of activated T cells (NFATC1³⁰), NK cells (NCR1³¹, KLRK1³²), and platelets (PF4³³), suggesting
212 these cells play a key role in the distinct biology of hyperinflammatory ARDS.

213

214 **Alignment with Experimental Models of Lung Injury**

215 IPA identified lipopolysaccharide (LPS), a component of gram-negative bacteria, as an
216 upstream regulator of genes differentially expressed between ARDS phenotypes
217 (Supplementary Data S2A) and in comparisons of each ARDS phenotype to controls
218 (Supplementary Data S2C and S2D). We hypothesized that genes upregulated in LPS models
219 of lung injury would be more upregulated in hyperinflammatory ARDS compared to controls than
220 in hypoinflammatory ARDS compared to controls. Respiratory tract gene expression data was
221 available from four LPS models of ARDS in the Gene Expression Omnibus. We also identified

222 17 more datasets from other experimental models of ARDS including ventilator-induced lung
223 injury (VILI), ozone, hyperoxia, Pam3Cys (a TLR2 agonist), and hemorrhagic shock
224 (Supplementary Data S3A). Gene sets from four models were significantly enriched (FDR < 0.1)
225 in TA from both ARDS phenotypes (Figure 1B; Supplementary Data S3B and S3C). As
226 expected, LPS models had a significant overlap with both phenotypes, but LPS experimental
227 gene sets had higher GSVA scores in hyperinflammatory participants. In addition, gene sets
228 from two ozone models, two LPS models, and one VILI model were enriched in
229 hyperinflammatory ARDS but not in hypoinflammatory ARDS, suggesting these models better
230 replicated dysregulated gene expression observed in the hyperinflammatory phenotype.

231

232 ***In silico* analysis of candidate drugs for hyperinflammatory ARDS**

233 To identify candidate treatments for the hyperinflammatory ARDS phenotype, we used
234 Upstream Regulator Analysis to identify drugs predicted to decrease expression of genes
235 upregulated in hyperinflammatory ARDS compared to hypoinflammatory ARDS or controls
236 (Figure 1C). For example, dexamethasone, which decreases interferon-gamma signaling³⁴, was
237 predicted to shift gene expression away from hyperinflammatory ARDS. Interestingly, several
238 drugs which cause drug-induced pneumonitis (e.g., nitrofurantoin, amiodarone, and cytarabine)
239 were predicted to shift gene expression from controls toward hyperinflammatory ARDS
240 (Supplementary Data S2C).

241

242 **Single-cell RNA-sequencing**

243 We used a neutrophil-preserving scRNASeq method to study TA from nine COVID-
244 negative patients with ARDS enrolled in a separate observational cohort (COMET; described in
245 Methods). TA scRNASeq was available from five participants with hypoinflammatory ARDS and
246 four with hyperinflammatory ARDS; clinical characteristics of these patients are provided in

247 Supplementary Table 1. 26,429 cells passed quality filters, and we used SingleR³⁵ to identify
248 cell types (Figure 2A). Neutrophils were the most common cell in both phenotypes (Figure 2B),
249 *CellChat* predicted markedly higher interaction between T cells and other cell types in
250 the hyperinflammatory phenotype (Figure 2C), which was consistent with the bulk analysis
251 predicting increased T cell activation. Phenotype-specific differences in cell-cell signaling were
252 driven by ligand-receptor pairs in several pathways (Figure 2D; Supplementary Figure 6A and
253 6B). In the hyperinflammatory phenotype, *CellChat* predicted increased MHC-I signaling, which
254 was driven by increased signaling to CD8 on T cells and NK cells. In contrast, MHC-II activity
255 was predicted to be higher in hypoinflammatory ARDS. *CellChat* also identified increased
256 NAMPT signaling by NK and T cells to integrin $\alpha 5\beta 1$ on monocytes, macrophages, and
257 dendritic cells in hyperinflammatory ARDS (Supplementary Data 6). Notably, NAMPT
258 polymorphisms are associated with a 7.7-fold increased risk of sepsis-associated ARDS³⁶ and
259 NAMPT was identified as an upstream regulator of differential gene expression in our bulk
260 RNASeq data (Figure 1C). These results further supported the hypothesis that there are marked
261 differences in respiratory tract signaling between phenotypes driven by differences in T and NK
262 cell signaling.

263 We next used *MAST* to compare differential gene expression in TA neutrophils, T cells,
264 monocyte-derived macrophages, and monocytes (Supplementary Figure 4, Supplementary
265 Data S4). We used IPA to identify upstream regulators of gene expression and analysis
266 identified several cell-specific differences in gene expression (Figure 2E, Supplementary Data
267 S5). Notably, some cytokines that were predicted to be activated in hyperinflammatory ARDS in
268 the bulk RNA sequencing data, including TNF and IFNG, were relatively less active in
269 neutrophils and monocytes from hyperinflammatory TA samples. In contrast, interferon lambda,
270 which is produced by the respiratory epithelium, was predicted to be more activated in
271 hyperinflammatory neutrophils and T cells. IPA also predicted increased activation of cell

272 activation of the integrated stress response (XBP1, EIF2AK2) and TLR4 in T cells from the
273 hyperinflammatory phenotype (Supplementary Data S5D).

274

275 **Plasma proteomic analysis identifies additional cytokines upregulated in** 276 **hyperinflammatory ARDS**

277 To further validate the biologic relevance of the TA findings, we measured plasma
278 concentrations of 96 protein biomarkers. 21 participants included in the TA bulk sequencing
279 analysis had protein biomarker data available, as did four participants from the same cohort who
280 did not have TA bulk sequencing available. Of these 25 participants, five had hyperinflammatory
281 ARDS and 20 had hypoinflammatory ARDS (Supplementary Table 2). We compared these
282 subjects to 14 healthy controls (mean age: 38, 43% female) and included in a previously
283 published analysis²².

284 Plasma concentrations of 28 proteins were higher in hyperinflammatory ARDS than in
285 hypoinflammatory ARDS (FDR < 0.1, Figure 3A). Some of these biomarkers confirmed known
286 differences between phenotypes, including higher concentrations of IL6 and TNF in
287 hyperinflammatory ARDS. Nine of these biomarkers were also elevated in hyperinflammatory
288 ARDS compared to controls but were not elevated in hypoinflammatory ARDS (Figure 3B and
289 3C), suggesting they identify distinctly dysregulated pathways in the hyperinflammatory
290 phenotype. These proteins included IL-8, which is one of the cytokines that defines the
291 hyperinflammatory phenotype; CASP-8, an effector of FAS signaling³⁷; interferon-induced
292 proteins CXCL9 and CXCL10³⁸; plasma urokinase (uPA); oncostatin M; and adenosine
293 deaminase (ADA). In addition, CCL2/MCP-1 and the T cell activation marker CD5³⁹ were higher
294 in hyperinflammatory ARDS and in controls compared to hypoinflammatory ARDS. These
295 observations were consistent with differences in TA gene expression at both the bulk RNASeq
296 and scRNASeq level. Plasma proteins that were higher in controls than in ARDS subjects are
297 shown in Supplementary Figure S7.

298

299 **Discussion**

300 This analysis represents the first report of significant differences in pulmonary biology
301 between ARDS molecular phenotypes, which have previously been characterized primarily
302 using plasma biomarkers. In addition to confirming evidence of innate immune activation
303 suggested by prior data on circulating plasma biomarkers, these analyses identify several novel
304 pathways as relevant to the pathogenesis of hyperinflammatory ARDS, including interferon-
305 stimulated pathways, apoptosis, and T-cell signaling, and suggest that each ARDS phenotype
306 has distinct pulmonary pathobiology which could help identify new therapeutic targets.

307 We identified a central role of T and NK cells in coordinating dysregulated inflammation
308 in hyperinflammatory ARDS. Hyperinflammatory ARDS was associated with markedly higher
309 mucosal interferon-stimulated gene expression and T/NK cell activation in bulk sequencing of
310 TA. Network analysis of scRNASeq data was also consistent with a central role of T and NK
311 cells in hyperinflammatory ARDS. These analyses identified differences in APC to T/NK cell
312 signaling, with greater MHC-I to CD8 signaling in the hyperinflammatory phenotype. Single cell
313 differential expression also predicted increased activation of TLR4 and XBP1 in
314 hyperinflammatory ARDS, suggesting the integrated stress and innate immune responses are
315 upregulated in T cells from the hyperinflammatory phenotype. In contrast to prior literature on
316 ARDS^{40,41}, which has emphasized the role of neutrophils, activated macrophages, and alveolar
317 epithelial cells in ARDS pathogenesis, our observations suggest lymphocytes play an
318 underrecognized role in coordinating dysregulated inflammation in hyperinflammatory ARDS.

319 Some features that characterized the hyperinflammatory phenotype in bulk sequencing
320 (e.g., higher predicted activation of cytokines classically associated with an innate response)
321 were not observed in specific cell types in scRNASeq. This observation has several possible
322 explanations. First, the results in bulk RNA sequencing may be driven by differences in the
323 immune cell composition of TA in each phenotype, as suggested by our scRNASeq analyses.

324 Notably, a similar pattern of high interferon-stimulated gene expression in T cells but diminished
325 immune responses in macrophages has also been reported in severe COVID-19⁴². Second, the
326 bulk signals may be driven by highly activated cells that do not survive the scRNASeq
327 processing pipeline, as has been reported previously for activated macrophages and
328 neutrophils. Third, some signals observed in the bulk data may be driven by epithelial cells,
329 which were selected against in our scRNASeq pipeline (in favor of enriching for immune cell
330 populations) and are thus not well-represented.

331 Plasma proteomics identified increased concentrations of the interferon-stimulated
332 proteins CXCL9 and CXCL10 and the T cell activation marker CD5 in hyperinflammatory ARDS
333 but not in hypoinflammatory ARDS. Notably, in an alternative molecular phenotyping approach
334 that used *k*-means clustering of plasma biomarkers to categorize ARDS subjects into two
335 molecular phenotypes (“reactive” and “uninflamed”), plasma IFN γ is one of the defining
336 biomarkers of the higher mortality “reactive” phenotype⁴³. Taken together, these analyses
337 support a central role of mucosal interferons and T cell activation in hyperinflammatory ARDS.

338 To our knowledge, only one prior study has attempted to characterize the pulmonary
339 compartment in ARDS phenotypes⁴⁴. This study included 10 hypoinflammatory patients and 16
340 hyperinflammatory patients and found no difference between these groups in concentration of
341 several inflammatory protein biomarkers in mini-BAL samples or in the lung microbiome. Our
342 results may differ from these because of a larger sample size, differing analytic approaches,
343 differing sampling strategies, or some combination thereof.

344 We compared differentially expressed genes in clinical samples to experimental ARDS
345 models to determine the relevance of these models to each phenotype. An experimental model
346 combining intratracheal LPS *and* mechanical ventilation was the murine model with the
347 strongest overlap in gene expression with ARDS subjects in both phenotypes. This gene
348 signature was from an experiment demonstrating that a combined MV/LPS model generated
349 markedly higher neutrophilic inflammation in the lung than LPS or MV alone⁴⁵. In addition, gene

350 signatures from five LPS models were enriched in hyperinflammatory ARDS but were not
351 enriched in hypoinflammatory ARDS, suggesting that hypoinflammatory patients, on average,
352 have less of an overlap in respiratory biology with the preclinical models. Our results also
353 indicate that the overlap in gene expression between experimental models and clinical samples
354 is highly variable, even among models with similar injurious stimuli (e.g., among VILI models).
355 Further study is required to understand how best to model each phenotype experimentally and if
356 our observations partially explain why therapies that appear promising in pre-clinical models are
357 not effective in more heterogeneous clinical trial populations.

358 Our results have important implications for developing a precision approach to treating
359 ARDS⁴. The *in silico* analysis identified several candidate therapies that target the dysregulated
360 pathways identified in hyperinflammatory ARDS. Several of the candidate drugs, including
361 imatinib, dexamethasone, and metformin, decrease lung injury caused by LPS in experimental
362 models⁴⁶⁻⁴⁸, again suggesting LPS replicates important features of the hyperinflammatory
363 phenotype. Approximately one-third of candidate drugs identified using pathway analyses are
364 validated in *in vivo*⁴⁹ and these treatments require validation in further preclinical studies and
365 clinical trials.

366 Strengths of this study include transcriptomic analysis of samples from the focal organ of
367 injury in ARDS, providing a detailed picture of the pulmonary biology of both ARDS phenotypes,
368 and deepening of these observations with single-cell sequencing and peripheral blood
369 proteomics. The inclusion of non-ARDS ventilated controls allowed us to further characterize the
370 physiologic dysregulation in the phenotypes, rather than defining gene expression relative to
371 another pathologic state. This analysis also has some limitations. Bulk and single-cell RNASeq
372 samples were collected in separate cohorts, so we cannot integrate these analytical
373 approaches. Although TA contains fluid from the distal airspaces⁵⁰, more invasive BAL testing
374 may identify additional differences between the phenotypes.

375 In conclusion, an integrated, multi-omic analysis of ARDS molecular phenotypes
376 originally defined by clinical and plasma protein biomarkers suggests the hyperinflammatory
377 phenotype is characterized by increased interferon-stimulated gene expression coordinated by
378 T cell signaling in the lower respiratory tract. Our findings suggest that the respiratory tract
379 biology of these phenotypes is distinct and further supports the use of molecular phenotypes to
380 study acute lung injury biology and develop new treatments for ARDS.

381

382 **Materials and Methods**

383 **List of Supplementary Materials**

384 **Figure S1:** Subjects included in this analysis.

385 **Figure S2:** Volcano plots showing differential gene expression between (A) 10
386 hyperinflammatory ARDS and 31 hypoinflammatory ARDS subjects, (B) 10 hyperinflammatory
387 ARDS and 5 control subjects, and (C) 31 hypoinflammatory ARDS and 5 control subjects.

388 **Figure S3:** GSVA scores for signatures of ALI experimental models in TA transcriptomes from 5
389 control subjects, 31 hypoinflammatory ARDS subjects, and 10 hyperinflammatory ARDS
390 subjects.

391 **Figure S4:** Volcano plots showing differential gene expression in scRNASeq for 5
392 hypoinflammatory ARDS subjects and 4 hypoinflammatory ARDS subjects in the COMET
393 cohort.

394 **Figure S5:** Circos plots displaying differentially interactive ligand-receptor pairs identified by
395 CellChat in a comparison of scRNASeq from 5 hypoinflammatory and 4 hyperinflammatory
396 ARDS subjects. (A) Pairs that are relatively higher in hyperinflammatory ARDS and (B) Pairs
397 that are relatively higher in hypoinflammatory ARDS.

398 **Figure S6:** Heatmaps for plasma proteins that are significantly higher in (A) Controls vs.
399 hyperinflammatory ARDS and (B) Controls vs. hypoinflammatory ARDS

400 **Figure S7:** Heatmap showing estimated power to detect a difference between phenotypes in
401 the Acute Lung Injury in Critical Illness cohort based on effect size and within-group coefficient
402 of variation.

403

404 **Supplementary Data S1:** Differential gene expression for pairwise comparisons of bulk RNA
405 gene expression for TA in the Acute Lung Injury in Critical Illness cohort. A positive \log_2 fold
406 difference indicates the gene is more highly expressed in the first group compared to second

407 group for each comparison. (A) Hyperinflammatory ARDS vs. hypoinflammatory ARDS; (B)
408 Hyperinflammatory ARDS vs. hypoinflammatory ARDS after adjusting for fungal infections; (C)
409 Hyperinflammatory ARDS vs. controls; and (D) Hypoinflammatory ARDS vs. controls; and (E)
410 All ARDS subjects vs. controls.

411
412 **Supplementary Data S2:** IPA Upstream Regulator scores for pairwise comparisons of bulk
413 RNA gene expression for TA in the Acute Lung Injury in Critical Illness Cohort. A positive z-
414 score indicates gene expression is consistent with higher activity of the upstream regulator in
415 the first group compared to second group for each comparison. (A) Hyperinflammatory ARDS
416 vs. hypoinflammatory ARDS; (B) Hyperinflammatory ARDS vs. controls; (C) Hypoinflammatory
417 ARDS vs. controls; and (D) All ARDS vs. controls.

418
419 **Supplementary Data S3:** (A) 200 most upregulated genes in experimental models of lung injury
420 compared to controls for 21 experimental systems in the Gene Expression Omnibus. (B) Gene
421 set enrichment analysis scores and leading-edge genes for experimental model gene sets in TA
422 differential expression for hyperinflammatory ARDS vs. controls. (C) Gene set enrichment
423 analysis scores and leading-edge genes for experimental model gene sets in TA differential
424 expression for hypoinflammatory ARDS vs. controls.

425
426 **Supplementary Data S4:** Differential gene expression for single-cell RNA sequencing for TA
427 for the COMET cohort. A positive \log_2 fold difference indicates the gene is more highly
428 expressed in hyperinflammatory ARDS. (A) Neutrophils, (B) Monocytes, (C) Monocyte-derived
429 macrophages, (D) T cells

430
431 **Supplementary Data S5:** IPA Upstream Regulator scores for pairwise comparisons of bulk
432 RNA gene expression for TA in the COMET. A positive z-score indicates gene expression is

433 consistent with higher activity of the upstream regulator in the hyperinflammatory ARDS
434 samples. (A) Neutrophils, (B) Monocytes, (C) Monocyte-derived macrophages, (D) T cells
435

436 **Supplementary Data S6:** CellChat results for ligand-receptor pairs in TA scRNASeq from the
437 COMET cohort for (A) hyperinflammatory ARDS and (B) hypoinflammatory ARDS.
438

439 **Supplementary Data S7:** (A) Z-scaled O-link protein concentrations for five hyperinflammatory
440 ARDS, 20 hypoinflammatory ARDS, and 14 control subjects. (B) Results of Wilcoxon rank-sum
441 tests for pairwise comparisons of hyperinflammatory ARDS, hypoinflammatory ARDS, and
442 control subjects.
443

444

445 References

- 446 1 Matthay MA, Zemans RL, Zimmerman GA, *et al.* Acute respiratory distress syndrome. *Nature*
447 *Reviews Disease Primers* 2019; **5**: 1–22.
- 448 2 RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19.
449 *New England Journal of Medicine* 2021; **384**: 693–704.
- 450 3 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-
451 19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; **397**:
452 1637–45.
- 453 4 Beitler JR, Thompson BT, Baron RM, *et al.* Advancing precision medicine for acute
454 respiratory distress syndrome. *Lancet Respir Med* 2021; : S2213-2600(21)00157-0.
- 455 5 Calfee CS, Delucchi K, Parsons PE, *et al.* Subphenotypes in acute respiratory distress
456 syndrome: latent class analysis of data from two randomised controlled trials. *The Lancet*
457 *Respiratory Medicine* 2014; **2**: 611–20.
- 458 6 Famous KR, Delucchi K, Ware LB, *et al.* Acute respiratory distress syndrome subphenotypes
459 respond differently to randomized fluid management strategy. *American Journal of*
460 *Respiratory and Critical Care Medicine* 2017; **195**: 331–338.
- 461 7 Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS. Latent class
462 analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured
463 lungs from sepsis (SAILS) study. *Intensive Care Medicine* 2018; **44**: 1859–69.
- 464 8 Sinha P, Delucchi KL, Chen Y, *et al.* Latent class analysis-derived subphenotypes are
465 generalisable to observational cohorts of acute respiratory distress syndrome: a prospective
466 study. *Thorax* 2021; published online July 5. DOI:10.1136/thoraxjnl-2021-217158.
- 467 9 Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. *The Lancet* 2021;
468 **398**: 622–37.
- 469 10 Maddali MV, Churpek M, Pham T, *et al.* Validation and utility of ARDS subphenotypes
470 identified by machine-learning models using clinical data: an observational, multicohort,
471 retrospective analysis. *Lancet Respir Med* 2022; **10**: 367–77.
- 472 11 Calfee CS, Delucchi KL, Sinha P, *et al.* Acute respiratory distress syndrome subphenotypes
473 and differential response to simvastatin: secondary analysis of a randomised controlled trial.
474 *Lancet Respir Med* 2018; **6**: 691–8.
- 475 12 Sinha P, Furfaro D, Cummings MJ, *et al.* Latent Class Analysis Reveals COVID-19–related
476 Acute Respiratory Distress Syndrome Subgroups with Differential Responses to
477 Corticosteroids. *Am J Respir Crit Care Med* 2021; **204**: 1274–85.
- 478 13 Chen H, Xie J, Su N, *et al.* Corticosteroid Therapy Is Associated With Improved Outcome in
479 Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest* 2021; **159**:
480 1793–802.

- 481 14Sinha P, Delucchi KL, McAuley DF, O’Kane CM, Matthay MA, Calfee CS. Development and
482 validation of parsimonious algorithms to classify acute respiratory distress syndrome
483 phenotypes: a secondary analysis of randomised controlled trials. *Lancet Respir Med* 2020;
484 **8**: 247–57.
- 485 15Bos LDJ, Artigas A, Constantin J-M, *et al.* Precision medicine in acute respiratory distress
486 syndrome: workshop report and recommendations for future research. *European Respiratory*
487 *Review* 2021; **30**. DOI:10.1183/16000617.0317-2020.
- 488 16Langelier C, Kalantar KL, Moazed F, *et al.* Integrating host response and unbiased microbe
489 detection for lower respiratory tract infection diagnosis in critically ill adults. *Proceedings of*
490 *the National Academy of Sciences* 2018; **115**: E12353 E12362.
- 491 17ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. *JAMA*
492 2012; **307**: 2526–33.
- 493 18Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–
494 associated infection and criteria for specific types of infections in the acute care setting.
495 *American Journal of Infection Control* 2008; **36**: 309–32.
- 496 19Sinha P, Churpek MM, Calfee CS. Machine Learning Classifier Models Can Identify Acute
497 Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. *Am J*
498 *Respir Crit Care Med* 2020; **202**: 996–1004.
- 499 20Tsitsiklis A, Zha B, Byrne A, *et al.* Impaired immune signaling and changes in the lung
500 microbiome precede secondary bacterial pneumonia in COVID-19. *Res Sq* 2021; published
501 online April 23. DOI:10.21203/rs.3.rs-380803/v1.
- 502 21Jin S, Guerrero-Juarez CF, Zhang L, *et al.* Inference and analysis of cell-cell communication
503 using CellChat. *Nat Commun* 2021; **12**: 1088.
- 504 22Combes AJ, Courau T, Kuhn NF, *et al.* Global absence and targeting of protective immune
505 states in severe COVID-19. *Nature* 2021; **591**: 124–30.
- 506 23Gundersen GW, Jones MR, Rouillard AD, *et al.* GEO2Enrichr: browser extension and server
507 app to extract gene sets from GEO and analyze them for biological functions. *Bioinformatics*
508 2015; **31**: 3060–2.
- 509 24Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and
510 RNA-Seq data. *BMC Bioinformatics* 2013; **14**: 7.
- 511 25Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-
512 sequencing and microarray studies. *Nucleic Acids Research* 2015; **43**: e47.
- 513 26Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy
514 and vaccine design. *Nat Rev Immunol* 2006; **6**: 595–601.
- 515 27Boyle AJ, Ferris P, Bradbury I, *et al.* Baseline plasma IL-18 may predict simvastatin treatment
516 response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical
517 trial. *Crit Care* 2022; **26**: 164.

- 518 28Stanifer ML, Guo C, Doldan P, Boulant S. Importance of Type I and III Interferons at
519 Respiratory and Intestinal Barrier Surfaces. *Frontiers in Immunology* 2020; **11**.
520 <https://www.frontiersin.org/articles/10.3389/fimmu.2020.608645> (accessed Dec 7, 2022).
- 521 29Caulfield AJ, Lathem WW. Disruption of Fas-Fas Ligand Signaling, Apoptosis, and Innate
522 Immunity by Bacterial Pathogens. *PLOS Pathogens* 2014; **10**: e1004252.
- 523 30Lee J-U, Kim L-K, Choi J-M. Revisiting the Concept of Targeting NFAT to Control T Cell
524 Immunity and Autoimmune Diseases. *Frontiers in Immunology* 2018; **9**.
525 <https://www.frontiersin.org/articles/10.3389/fimmu.2018.02747> (accessed Dec 7, 2022).
- 526 31Walzer T, Bléry M, Chaix J, *et al.* Identification, activation, and selective in vivo ablation of
527 mouse NK cells via NKp46. *Proceedings of the National Academy of Sciences* 2007; **104**:
528 3384–9.
- 529 32Bauer S, Groh V, Wu J, *et al.* Activation of NK Cells and T Cells by NKG2D, a Receptor for
530 Stress-Inducible MICA. *Science* 1999; **285**: 727–9.
- 531 33Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and
532 inflammation. *Nat Immunol* 2013; **14**: 768–70.
- 533 34Hu X, Li W-P, Meng C, Ivashkiv LB. Inhibition of IFN- γ Signaling by Glucocorticoids¹. *The*
534 *Journal of Immunology* 2003; **170**: 4833–9.
- 535 35Aran D, Looney AP, Liu L, *et al.* Reference-based analysis of lung single-cell sequencing
536 reveals a transitional profibrotic macrophage. *Nat Immunol* 2019; **20**: 163–72.
- 537 36Ye SQ, Simon BA, Maloney JP, *et al.* Pre-B-Cell Colony-enhancing Factor as a Potential
538 Novel Biomarker in Acute Lung Injury. *Am J Respir Crit Care Med* 2005; **171**: 361–70.
- 539 37Muzio M, Chinnaiyan AM, Kischkel FC, *et al.* FLICE, A Novel FADD-Homologous ICE/CED-
540 3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex.
541 *Cell* 1996; **85**: 817–27.
- 542 38Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC
543 chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse
544 RENCA tumor. *J Immunol* 1998; **161**: 927–32.
- 545 39Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 Expression Is
546 Developmentally Regulated By T Cell Receptor (TCR) Signals and TCR Avidity. *Journal of*
547 *Experimental Medicine* 1998; **188**: 2301–11.
- 548 40Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and
549 phenotypes. *The Lancet* 2022; **400**: 1145–56.
- 550 41Matthay MA, Zemans RL, Zimmerman GA, *et al.* Acute respiratory distress syndrome. *Nat*
551 *Rev Dis Primers* 2019; **5**: 1–22.
- 552 42Yao C, Bora SA, Parimon T, *et al.* Cell-Type-Specific Immune Dysregulation in Severely Ill
553 COVID-19 Patients. *Cell Reports* 2021; **34**: 108590.

- 554 43Bos LD, Schouten LR, van Vught LA, *et al.* Identification and validation of distinct biological
555 phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax*
556 2017; **72**: 876–83.
- 557 44Heijnen NFL, Hagens LA, Smit MR, *et al.* Biological subphenotypes of acute respiratory
558 distress syndrome may not reflect differences in alveolar inflammation. *Physiological Reports*
559 2021; **9**: e14693.
- 560 45Altemeier WA, Matute-Bello G, Gharib SA, Glenny RW, Martin TR, Liles WC. Modulation of
561 Lipopolysaccharide-Induced Gene Transcription and Promotion of Lung Injury by Mechanical
562 Ventilation. *The Journal of Immunology* 2005; **175**: 3369–76.
- 563 46Stephens RS, Johnston L, Servinsky L, Kim BS, Damarla M. The tyrosine kinase inhibitor
564 imatinib prevents lung injury and death after intravenous LPS in mice. *Physiol Rep* 2015; **3**:
565 e12589.
- 566 47Yang J-W, Mao B, Tao R-J, *et al.* Corticosteroids alleviate lipopolysaccharide-induced
567 inflammation and lung injury via inhibiting NLRP3-inflammasome activation. *Journal of*
568 *Cellular and Molecular Medicine* 2020; **24**: 12716–25.
- 569 48Zhang Y, Zhang H, Li S, Huang K, Jiang L, Wang Y. Metformin Alleviates LPS-Induced Acute
570 Lung Injury by Regulating the SIRT1/NF- κ B/NLRP3 Pathway and Inhibiting Endothelial Cell
571 Pyroptosis. *Front Pharmacol* 2022; **13**: 801337.
- 572 49Felciano RM, Bavari S, Richards DR, *et al.* Predictive systems biology approach to broad-
573 spectrum, host-directed drug target discovery in infectious diseases. *Pac Symp Biocomput*
574 2013; : 17–28.
- 575 50Bernhard W, Haagsman HP, Tschernig T, *et al.* Conductive airway surfactant: surface-
576 tension function, biochemical composition, and possible alveolar origin. *Am J Respir Cell Mol*
577 *Biol* 1997; **17**: 41–50.
- 578

579 **Acknowledgments:**

580 **Funding:**

581 National Institutes of Health grant F32HL151117 (AS)
582 National Institutes of Health grant R35HL140026 (CSC)
583 National Institutes of Health grant 2R24AA019661-06A1 (CSC)
584 National Institutes of Health grant K23HL138461-01A1 (CRL)
585 National Institutes of Health grant U19AI1077439 (DJE, CSC)
586 University of California San Francisco ImmunoX CoLabs
587 Chan Zuckerberg Foundation 2019-202665
588 Genentech TSK-020586

589
590 **Author contributions:**

591 Conceptualization: AS, SAC, CSC
592 Formal analysis/software: AS, SAC, AOP, LPAN, EM, MVM, AB, KLK
593 Data curation: HZ, AJ, RG, SC, TD
594 Investigation: AS, BSZ, PS, JGW, FM, AL, ERS, ZML, RG, SC, PHS, TD, CL, KNK,
595 CMH, MAM, CRL, CSC
596 Visualization: AS
597 Funding acquisition: AS, CRL, DJE, CSC
598 Project administration: JLD, DJE, MFK, KNK, CMH, PGW, MAM, CRL, CSC
599 Supervision: SAC, CRL, CSC
600 Writing – original draft: AS
601 Writing – review & editing: All authors

602
603 **Competing interests:** Authors declare that they have no competing interests.

604
605 **Data and materials availability:**

606 Code for differential expression and scRNASeq analyses is available at
607 <https://github.com/AartikSarma/ARDSPhenotypes>

608
609 The processed gene count data are available from the National Center for Biotechnology
610 Information Gene Expression Omnibus database under accession code GSE200849. The raw
611 sequencing data used in this analysis are protected due to data privacy restrictions from the IRB
612 protocols governing patient enrollment in this study, which protect the release of raw genetic
613 sequencing data from those patients enrolled under a waiver of consent. Researchers who wish
614 to obtain raw FASTQ files for the purposes of independently generating gene counts can
615 contact the corresponding author (aartik.sarma@ucsf.edu) to be added to the IRB protocols and
616 sign a materials transfer agreement from UCSF ensuring that the data will be securely stored
617 and only utilized for transcriptomic analyses.

18 **Figure 1: Bulk RNA sequencing analyses of TA collected in the Acute Lung Injury in Critical Illness**

19 **cohort. (A)** Upstream regulator z-scores based on IPA analysis of differential gene expression in pairwise
20 comparisons of tracheal aspirate bulk RNA sequencing in hyperinflammatory ARDS (N=10), hypoinflammatory
21 ARDS (N=31), and mechanically ventilated controls (N=5). A positive z-score indicates differential gene
22 expression is consistent with greater activation of the upstream regulator of gene expression in the first group
23 in each pairwise comparison. Circles identify upstream regulators that are statistically significant. **(B)** Gene set
24 variation analysis for experimental models of lung injury. GSVA scores were calculated for each sample, and
25 the difference between hyperinflammatory ARDS and controls (orange) and hypoinflammatory ARDS and
26 controls (blue) was estimated with limma. For each model, the GEO Accession Number, organism, and lung
27 injury model are listed on the x-axis. **(C)** Upstream regulator scores for selected drugs in the IPA database that
28 are predicted to significantly shift gene expression away from hyperinflammatory ARDS in independent
29 analyses of differential gene expression with hypoinflammatory ARDS (blue) or controls (green).

30 **Figure 2: TA single-cell RNA sequencing. (A)** Seurat UMAP projection of 26,429 TA cell transcriptomes

31 from four participants with hyperinflammatory ARDS and five participants with hypoinflammatory ARDS,
32 annotated with cell type as predicted by SingleR. **(B)** UMAP projection of TA cells transcriptomes separated by
33 ARDS phenotype. **(C)** Differential interaction between cell types predicted by CellChat. Red arrows identify cell
34 pairs with greater strength of interaction in hyperinflammatory ARDS. **(D)** Differences in strength of ligand-
35 receptor interaction for pathways in the CellChat database. **(E)** Upstream regulator analysis z-scores for
36 differentially expressed genes in neutrophils, monocytes, monocyte-derived macrophages, and T cells. A
37 positive z-score indicates the upstream regulator is predicted to be more highly activated in hyperinflammatory
38 ARDS. Circles identify upstream regulators that were statistically significant.

39 **Figure 3: O-Link proteomics results for plasma biomarkers from 5 hyperinflammatory ARDS, 20**

40 **hypoinflammatory ARDS, and 14 control participants.** Each heatmap shows plasma protein biomarkers
41 that were significantly different between groups (FDR < 0.1); for a complete list of proteins, see Supplementary
42 Data S7. Each column represents an individual subject, and each row shows the z-scaled concentrations.
43 Rows and columns are clustered using the Euclidean distance. Columns are annotated by phenotype. Z-score
44 for expression is shown on the color bar on the right. **(A)** Hyperinflammatory ARDS vs. hypoinflammatory

- 15 ARDS (*: proteins that higher in hyperinflammatory ARDS vs. volunteers but not difference between
16 hypoinflammatory ARDS and controls; ‡: proteins that are higher in hyperinflammatory ARDS vs. volunteers
17 and lower in hypoinflammatory ARDS vs. volunteers) **(B)** Hyperinflammatory ARDS vs. healthy volunteers. **(C)**
18 Hypoinflammatory ARDS vs. healthy volunteers.


	Hyperinflammatory	Hypoinflammatory	P (1)	Control	P (2)	P (3)
N	10	31		5		
Age	66 [56, 72]	63 [51, 70]	0.63	66 ± 23	0.85	0.42
Female	4 (40)	21 (68)	0.95	3 (60)	0.26	0.49
BMI (kg/m²)	25.0 [23.6, 25.6]	25.9 [23.9, 32.2]	0.27	25.7 ± 4.8	0.24	0.23
Vasopressors at enrollment	9 (90)	19 (61)	0.19	1 (20)	<0.01	0.21
Minimum PF ratio (mmHg)	76 [62, 97]	93 [67, 138]	0.25	296 [216,366]	<0.01	<0.01
SOFA score at enrollment	18 [16, 19]	9 [7, 11]	<0.01	5 [4, 5]	<0.01	<0.01
IL-8, pg/ml	424 [228, 1068]	15 [9, 25]	<0.01	10 [8, 11]	<0.01	0.21
Protein C, % control	51 [31, 62]	103 [76, 132]	<0.01	115 [79, 148]	<0.01	0.76
Immunosuppression	4 (40)	6 (19)	0.37			
Primary ALI Risk Factor			0.79			
<i>Pneumonia</i>	4 (40)	16 (48)				
<i>Sepsis</i>	4 (40)	7 (23)				
<i>Aspiration</i>	2 (20)	6 (23)				
<i>Pancreatitis</i>	0 (0)	1 (3)				
<i>None</i>	0 (0)	1 (3)				
Clinical respiratory microbiology						
<i>Respiratory viral pathogen</i>	1 (10)	1 (3)	0.98			
<i>Respiratory bacterial pathogen</i>	3 (30)	11 (36)	1.00			

649


650 **Table 1:** Characteristics of patients included in differential expression analysis of ARDS phenotypes from the Acute Lung Injury in
651 Critical Illness cohort. Normally distributed values are reported as mean ± SD. Non-normally distributed values are reported as
652 median [IQR]. Categorical data are reported as N (% of total for category). P-values are for a t-test for normally distributed

653 continuous data, Wilcoxon rank-sum for non-normally distributed, and chi-square test for categorical data. P values are for (1)
654 hyperinflammatory ARDS vs. hypoinflammatory ARDS; (2) hyperinflammatory ARDS vs. controls; (3) hypoinflammatory ARDS vs.
655 controls

A



B



C

